Abstract
A total of 493 melanoma patients were investigated by 20 European nuclear medicine departments by means of the saine99mTc-labelled immunoradiopharmaceutical and the same immunoscintigraphy (ISG) protocol. (i) No chemical or clinical toxicity was detected during or following the studies. (ii) Positive results were obtained in 287/363 (79%) patients (321 carrying known lesions and 42 carrying previously occult lesions): in 231 (80%) of them, 402/402 lesions were imaged, in the remaining 56 ISG-positive patients, 108/204 lesions were imaged; in 76 patients 0/122 lesions were ïmaged. (iii) The fraction of melanoma lesions visualized by ISG was 510/728 (70A%); 605 of these lesions were already documented at the time of the study, and 123 were previously occult. (iv) A total of 218 documented melanoma lesions (30%) were not visualized by ISG in 132 patients: about 70% of the ISG-negative lesions were of small size (less than 2 cm diameter). (v) The melanoma nature of 69/123 previously occult lesions was confirmed by clinical criteria and/or additional investigations in follow-up studies. The results obtained in this study are similar to those obtained in the Italian Multicentre Study which had previously been carried out with 258 melanoma patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bockisch A, Hotze A, Biltz H, Ochr P, Kreysel HW, Biersack HJ (1989) Radioimmunodetection (RID) in malignant melanoma - a controlled clinical study. In: Schmidt HAE, Buraggi GL (eds) Nuclear medicine - trends and possibilities in nuclear medicine. Schattauer, Stuttgart, pp 570–573
Bomanji J, Garner A, Prasad J, Albert DM, Hungerford JL, Granowska M, Britton KE (1987a) Characterisation of ocular melanoma with cutaneous melanoma antibodies. Br J Ophthalmol 71:647–650
Bomanji J, Hungerford JL, Granowska M, Britten KE (1987b) Radioimmunoscintigraphy of ocular melanoma with99mTc labelled cutaneous melanoma antibody fragments. Br J Ophthalmol 71:651–658
Bomanji J, Nimmon CC, Hungerford JL, Solanki K, Granowska M, Britton KE (1988) Ocular radioimmunoscintigraphy: sensitivity and practical considerations. J Nucl Med 29:1038–1044
Boniolo A, Dovis M, Matteja R (1982) Use of an enzyme-linked immunosorbent assay for screening hybridoma antibodies against hepatitis B surface antigen. J Immunol Methods 49:1–15
Britton KE, Buraggi GL, Bares R, Bischof-Delaloye A, Buell U, Emrich D, Granowska M (1989) A brief guide to the practice of radioimmunoscintigraphy and radioimmunotherapy in cancer. Int J Biol Markers 4:106–118
Büll U, Weiher G, Hofstädter F (1986) Classification of a tumour in the popliteal fossa by radioimmunoscintigraphy 11 years after resection of a malignant melanoma. Int J Biol Markers 1:155–158
Buraggi GL, Callegaro L, Ferrone S, Turrin A, Cascinelli N, Attili A, Bembardieri E, Mariani G, Deleide G (1984a) In vivo immunodiagnosis with radiolabeled anti-melanoma antibodies and F(ab′)2 fragments. In: Schmidt HAE, Adam WE (eds) Nuklearmedizin. Schattauer, Stuttgart, pp 713–717
Buraggi GL, Callegaro L, Turrin A, Cascinelli N, Attili A, Emanuelli H, Gasparini M, Deleide G, Plassie G, Dovis M, Mariani G, Natali PG, Scassellati GA, Rosa U, Ferrone S (1984b) Immunoscintigraphy with123I,99mTc and111In-labelled F(ab′)2 fragments of monoclonal antibodies to a human high molecular-weight melanoma-assocated antigen. J Nucl Med Allied Sci 28:283–295
Buraggi GL, Turrin A, Cascinelli N, Attili A, Terne G, Bombardieri E, Gasparini M, Seregni E (1985a) Immunoscintigraphy with anti-melanoma monoclonal antibodies. In: Donato L, Britten KE (eds) Immunoscintigraphy. Gordon and Breach, New York, pp 215–254
Buraggi GL, Callegaro L, Mariani G, Turrin A, Cascinelli N, Attili A, Bembardieri E, Terne G, Plassie G, Dovis M, Mazzuca N, Natali PG, Scassellati GA, Rosa U, Ferrone S (1985b) Imaging with1311I-labelled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab′)2 fragments. Cancer Res 45:3378–3387
Buraggi GL, Callegaro L, Cascinelli N, Ferrene S, Turrin A, Attili A, Bembardieri E, Gasparini M, Deleide G, Scassellati GA, Seregni E (1986a) Radioimmunodetection of malignant melanoma with radiolabelled (131I,123I,111In,99mTc) monoclonal antibodies and F(ab′)2 fragments. In: Winkler C (ed) Nuclear Medicine in clinical oncology. Springer, Berlin Heidelberg New York, pp 207–214
Buraggi GL, Turrin A, Cascinelli N, Attili A, Gasparini M, Callegaro L, Ferrene S, Seregni E, Bembardieri E, Belli F (1986b) Radioimmunodetection of melanoma: preliminary results of a prospective study. Int J Biol Markers 1:47–54
Buraggi GL, Turrin A, Cascinelli N, Callegaro L, Gasparini M, Attili A, Bembardieri E, Belli F, Seregni E (1987) Clinical demands on radieimmunodetection of melanoma: the importance of prospective trials. In: Schmidt HAE, Emrich D (eds) Nuklearmedizin. Schattauer, Stuttgart, pp 411–413
Callegaro L, Deleide G, Devis M, Ceccenato E, Plassio G, Rosa U, Scassellati GA (1985) Purification and labelling of F(ab′)2 fragments from anti-tumor monoclonal antibodies and their conversion to radiopharmaceuticals. In: Denato L, Britton KE (eds) Immunoscintigraphy. Gordon and Breach, New York, pp 101–120
Cascinelli N, Attili A, Belli F, Buraggi GL, Turrin A, Gasparini M, Terne G, Vaglini M (1988) Anti-melanoma monoclonal antibody 225.28S: evaluation of texicity in man. Tumori 4:35–40
Cerny T, Owens SE, Mackenzie SA, Nuttall PM, Gosh AK, Smith DB, Thatcher N (1987) Immunoscintigraphy with99mTc labelled F(ab′)2 fragments of an anti melanoma monolonal antibody (225.28S) in patients with metastatic malignant melanoma. Eur J Nucl Med 13:130–133
De Haro J, Rames J, Suarez MG, Alhambra CA, Encinas JL, Maraña G (1988) Radioimmunodeteccion de los melanomas de ojo. In: Libro de Penencias del XIV Congreso Nactional de Medicina Nuclear, Bilbao, pp 173–180
Dudczak R, Kletter K, Bailer H, Kokoschka E, Pohl-Markl H (1987) Immunszintigraphie mit einem Technetium-99m-mar kierten monoclonalen Antikörper bei Patienten mit Melanom. Wien Klin Wochenschr 99:232–239
Eary JF, Schroff RW, Abrams PG, Fritzberg AR, Morgan AC, Kasina S, Reno JM, Srinivasan A, Woodhouse CS, Wilbur DS, Natale RB, Collins C, Stehlin JS, Mitchell M, Nelp WB (1989) Successful imaging of malignant melanoma with technetium-99m-labeled monoclonal antibodies. J Nucl Med 30:25–32
Galen RS, Gambino SR (1972) Beyond normality: the predictive value and efficiency of medical diagnoses. J Wiley & Sons, New York
Liewendahl K, Kairento AL, Pyrhönen S, Franssila K, Asko-Seljavaara S, Lindroth L, Virkkunen P, Lannes J (1986) Localization of melanoma with radiolabelled monoclonal antibody fragments and iodoamphetamine. Eur J Nucl Med 12:359–362
Lukac J, Spaventi S (1988) Immunoscintigraphy of melanoma with Tecnemab K-1 monoclonal antibody preparation. J Exp Clin Cancer Res 7:97–102
Mansi L, Venuta S, Ferrone S, Castello G, Giordano GG, Salvatore M (1984) In vivo evaluation of anti-melanoma antibody, F(ab′)2, labelled with Te-99m. In: Giraldo G, Beth E, Castello G, Giordano GG, Zarrilli D (eds) From oncogenes to tumor antigens. Elsevier, Amsterdam, pp 157–165
Natali PG, Giacomini P, Buraggi GL, Cavaliere R, Bigotti A, Callegaro L, Ferrone S (1984) Serological and binding characteristics of a monoclonal antibody (MoAb) to a human high molecular weight-melanoma associated antigen (HMW-MAA) for tumor imaging. In: Giraldo G, Beth E, Castello G, Giordano GG, Zarrilli D (eds) Front oncogenes to tumor antigens. Elsevier, Amsterdam, pp 127–134
Paganelli G, Riva P, Moscatelli G, Stacchiotti A, Agostini M, Landi G, Tison V, Panacea P, Siccardi AG (1986) Improved immunoscintigraphy by subcutaneous injection of99mTc or111In labelled F(ab′)2 fragments of an anti-melanoma monoclonal antibody. Nucl Med Biol 13:423–428
Rentsch M, Cerny T, Richner J, Brunner KW, Rösler H, Nachbur N (1989) Immunszintigraphie mit einem99mTc-markierten Melanomantikörper (HMW-MAA 225.28S, F(ab′)2 Fragmente: Tecnemab-K, Sorin Biomedica) bei Patienten mit malignem Melanom. Helv Chir Acta (in press)
Rhodes BA, Torvestad DA, Breslow K, Burchiel SW, Reed KA, Austin RK (1982)99mTc-labeling and acceptante testing of radiolabelled antibodies and antibody fragments. In: Burchiel SW, Rhodes BA (eds) Tumor imaging: the radiochemical detection of cancer. Masson Publ USA, New York, 15:111–123
Rhodes BA, Zamora PO, Newell KD, Valdez EF (1986) Technetium-99m labeling of murine monoclonal antibody fragments. J Nucl Med 27:685–693
Riva P, Paganelli G, Tison V, Fiorentini GM, Landi G, Amadori D (1985) Melanoma immunoscintigraphy with 99mTe-labelled monoclonal F(ab′)2: sensitivity and specificity studies. In: Donato L, Britton KE (eds) Immunoscintigraphy. Gordon and Breach, New York, pp 255–266
Salk D and the Multicenter Study Group (1989) Technetium-labeled monoclonal antibodies for imaging metastatic melanoma: results of a multicenter clinical study. Oncology 15:608–618
Schaling DF, Van Kroonenburgh MJPG, Borsje RA, Camps JAJ, Kakebeeke-Kemme HM, Oosterhuis JA, Pauwels EKJ (1989) Radioimmunoscintigraphy with melanoma-associated monoclonal antibody fragments in choroidal melanoma. Graefes Arch Clin Exp Ophthalmol 227:291–294
Scheidhauer K, Landthaler M, Wehmeyer G, Büll U, Moser E (1985) Wertigkeit der Immunszintigraphie mit99mTc-markierten monoklonalen Antikörpern gegen maligne Melanome. Radioimmunoszintigraphie Kolloquiumsberichte, Schloss Böttstein, pp 54–59
Scheidhauer K, Markl A, Leinsinger G, Moser E, Scheiffarth OF, Riedel KG, Schaal TS, Stefani FH, Schumacher U (1988) Immunoscintigraphy in intraocular malignant melanoma. Nucl Med Comm 9:669–679
Seccamani E, Deleide G, Malinverni A, Mariani M, Spranzi E, Scassellati GA (1989) Standardization of an immunoreactivity test for radiolabelled monoclonal antibodies. In: Schmidt HAE, Buraggi GL (eds) Nuclear medicine - trends and possibilities in nuclear medicine. Schattauer, Stuttgart, pp 709–711
Siccardi AG, Buraggi GL, Callegaro L, Mariani G, Natali PG, Abbati A, Bestagno M, Caputo V, Mansi L, Masi R, Paganelli G, Riva P, Salvatore M, Sanguineti M, Troncone L, Turco GL, Scassellati GA, Ferrone S (1986) Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res 46:4817–4822
Stehlin JS Jr, Clark RL, Vickers WE, Monges A (1963) Perfusion for malignant melanoma of the extremities. Am J Surg 105:607–614
Wilson BS, Imai K, Natali PG, Ferrone S (1981) Distribution and molecular characterization of a cell surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer 28:293–300
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Siccardi, A.G., Buraggi, G.L., Natali, P.G. et al. European multicentre study on melanoma immunoscintigraphy by means of99mTc-labelled monoclonal antibody fragments. Eur J Nucl Med 16, 317–323 (1990). https://doi.org/10.1007/BF00842787
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00842787